Novartis taps Hospira-sale engineer exec Ball to revive slumping Alcon

Novartis (NYSE:NVS) is looking to revitalize its slumping Alcon eye care division by picking up medical vet Michael Ball, who recently organized Hospira’s $15 billion sale to Pfizer (NYSE:PFE). Ball will replace previous Alcon chief Jeff George, the company announced today. Novartis CEO Joe Jimenez is reportedly putting Ball in control of reviving Alcon. Alcon has been in a rut, with its glaucoma drug Travatan Z patent expiring last month, intraocular lens implant revenue slumping and an underperforming over-the-counter contact lens solution biz. “If you look at the mistakes that were made that have led to the slowdown, we were not as vigilant enough… on ensuring that the innovation pipeline would result in continued growth. The 2nd is, I think we went a little too far on cost savings, we reduced some of the services that they had grown accustomed to at Alcon,” Jimenez said. Jimenez added that Alcon faces struggling surgical equipment sales and a lack of innovative products, as well as drooping customer loyalty as the company cut spending on training and education for surgeons. Alcon’s slump led Novartis as a whole to miss earnings forecast for 2015, with net income falling 5%, missing Street expectations. Novartis has missed forecasts for 3 straight quarters, and Jimenez predicted that 2016 will be mostly in line with 2015. Novartis is also facing another expiration, on its blood-cancer treatment drug Gleevec, which produces $3 billion in ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Optical/Ophthalmic Alcon Inc. Hospira Inc. Novartis AG Pfizer Inc. Source Type: news

Related Links:

A 54-year-old woman who presented with photopsia was found to have elevated intraocular pressure in both eyes and optic disc cupping in the right eye. Angle infiltration was noted on gonioscopy. She was previously been diagnosed with metastatic breast cancer. This case report describes a rare case of glaucoma as a complication of ciliary body and iris metastases secondary to invasive ductal breast cancer.
Source: Journal of Glaucoma - Category: Opthalmology Tags: Online Articles: Case Report/Small Case Series Source Type: research
Abstract Lysyl Oxidase Like 1 (LOXL1) is a gene that encodes for the LOXL1 enzyme. This enzyme is required for elastin biogenesis and collagen cross-linking, polymerising tropoelastin monomers into elastin polymers. Its main role is in elastin homeostasis and matrix remodelling during injury, fibrosis and cancer development. Because of its vast range of biological functions, abnormalities in LOXL1 underlie many disease processes. Decreased LOXL1 expression is observed in disorders of elastin such as Cutis Laxa and increased expression is reported in fibrotic disease such as Idiopathic Pulmonary Fibrosis. LOXL1 is ...
Source: Experimental Eye Research - Category: Opthalmology Authors: Tags: Exp Eye Res Source Type: research
AbstractAimTo analyze the socioeconomic conditions and health status of older persons living in 11 Quilombola communities (settlements originally created by escaped slaves) in the Baixada Maranhense region, Brazil.Subjects and methodsA cross-sectional household survey of the socioeconomic status, sanitary conditions, health behavior, and self-reported morbidities was conducted with 208 older persons. Fisher ’s exact test and the chi-squared test were performed (α = 5%) to determine statistically significant gender and age differences in the prevalence of morbidities and multimorbidities (≥ 2 an...
Source: Journal of Public Health - Category: Health Management Source Type: research
To determine the association between cancer diagnosis on medication adherence in patients with glaucoma.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original Articles Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Lingering populations of senescent cells grow with age, and cause considerable harm via their inflammatory secretions. They are a tool to promote regeneration and resistance to cancer in the short term, but like many short term systems, they become damaging when left switched on for the long term. As I noted just yesterday, even looking at only the past year of studies of senolytic therapies to selectively destroy senescent cells, there is strong evidence in animal models for their ability to prevent or reverse a score of common age-related conditions, a broad range from Alzheimer's disease and other forms of neurodegenera...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Publication date: Available online 17 December 2019Source: Pharmacological ResearchAuthor(s): Robert RoskoskiABSTRACTBecause genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry. The US FDA approved four small molecule protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib. Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumor...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
We reported an isolated case and 1 family with several individuals affected by CS. The isolated case showed typical features including fibrocystic breast disease, benign thyroid nodules, and multiple papillomatous lesions in the face and oral cavity and was caused by a novel nonsense mutation (c.940 G>T) in the PTEN gene. In the family, the proband showed erythema nodosum, duodenal ulcer, intestinal polyps, cervical lipoma, renal cysts, and glaucoma, whereas her family revealed multiple members with intestinal polyps and a sister with breast cancer diagnosed at early age.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
CONCLUSIONS The results suggest that by regulating the expression of BMPs, ANGPTL7 directly promotes proliferation, differentiation, and mineralization of osteoblasts. PMID: 31835268 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 26 November 2019Source: Life SciencesAuthor(s): Ejaz Aziz, Riffat Batool, Wasim Akhtar, Shazia Rehman, Tasmeena Shahzad, Ayesha Malik, Mohammad Ali Shariati, Alexey Laishevtcev, Sergey Plygun, Mojtaba Heydari, Abdur Rauf, Shaheer Ahmed ArifAbstractXanthophylls constitute a major part of carotenoids in nature. They are an oxidized version of carotenoid. Xanthophyll has widely drawn scientists' attentions in terms of its functionality, bioavailability and diversity. An assortment of xanthophyll varieties includes lutein, zeaxanthin, β-cryptoxanthin, capsanthin, astaxanthin, and fucoxan...
Source: Life Sciences - Category: Biology Source Type: research
More News: Cancer | Cancer & Oncology | Education | Glaucoma | Gleevec | Medical Devices | Opthalmology | Pfizer | Training | Travatan | Universities & Medical Training